deaths (OS)progression or deaths (PFS)RFS/DFS

laHNSCC - 1st line (L1) locally advanced (laHNSCC) laHNSCC - 1st line (L1)

versus placebo
avelumab alone vs. placebo 1 certainty unassessable+31% certainty unassessable+21%-